详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Genetic lesions and targeted therapy in Hodgkin lymphoma

90| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [2]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Hankou, Wuhan 430030, China.

出处：

DOI：

ISSN：

关键词： CAR-T therapy Hodgkin lymphoma immune evasion immunotherapy JAK-STAT molecular mechanisms NFκB primary immunodeficiency targeted therapies

摘要：

Hodgkin lymphoma is a special type of lymphoma in which tumor cells frequently undergo multiple genetic lesions that are associated with accompanying pathway abnormalities. These pathway abnormalities are dominated by active signaling pathways, such as the JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway and the NFκB (nuclear factor kappa-B) pathway, which usually result in hyperactive survival signaling. Targeted therapies often play an important role in hematologic malignancies, such as CAR-T therapy (chimeric antigen receptor T-cell immunotherapy) targeting CD19 and CD22 in diffuse large B-cell lymphoma, while in Hodgkin lymphoma, the main targets of targeted therapies are CD30 molecules and PD1 molecules. Drugs targeting other molecules are also under investigation. This review summarizes the actionable genetic lesions, current treatment options, clinical trials for Hodgkin lymphoma and the potential value of those genetic lesions in clinical applications.© The Author(s), 2023.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版中科院分区表Review为是的期刊

：

大类 | 2 区医学

小类 | 2 区血液学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区血液学

JCR分区：

出版当年[2021]版：

Q2 HEMATOLOGY

最新[2023]版：

Q2 HEMATOLOGY

影响因子： 3.4 最新[2023版] 3.5 最新五年平均 5.4 出版当年[2021版] 4.381 出版当年五年平均 7.167 出版前一年[2020版] 3.4 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

通讯作者：

通讯机构： [2]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Hankou, Wuhan 430030, China. [*1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Hankou, Wuhan 430030, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy [2]Advances in Universal CAR-T Cell Therapy [3]Dawn of CAR-T cell therapy in autoimmune diseases [4]CAR T Cell Therapy for Hematological Malignancies [5]Innovative strategies to advance CAR T cell therapy for solid tumors [6]Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK plus ALCL [7]Chidamide Bridging for CAR-T Therapy [8]JAK/STAT信号通路在肺癌中的研究进展 [9]Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations [10]CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome